• Institute of Good Manufacturing Practices India
  • Global accredited training & certification provider
  • Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India
  • Approved Training Institute of Food Safety and Standards Authority of India (FSSAI)
  • Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India
  • An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
  • Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh
  • Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC) set up by National Skill Development Corporation (NSDC)
  • Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017

Trusted by organizations & training participants in over 30 countries
Training | Certification | Education | Research

National Drugs Database is being developed by CDSCO to manage supply and quality issues

Central Drugs Standard Control Organization (CDSCO) is creating a comprehensive national digital database of pharmaceutical manufacturers and the medicines they produce as currently there is no comprehensive, real-time information on medicine makers in India which poses serious challenges.

According to a senior CDSCO official, "a national database has become extremely important as many states have their own databases on different software and all that data needs to be integrated into a centralized database". This is also required as according to Dinesh Abrol, who is a long time pharmaceutical industry watcher from the Institute for Studies in Industrial Development," Many state licensing authorities have been licensing irrational combinations, which should not be allowed at all, but they are being produced and marketed."

Availability of a national database is required from the policy planning and monitoring aspect as to know who produces what medicines and how and will have the below mentioned benefits:
1) Digitization would enable better sharing of information between regulators in all states and the centre so that they can harmonize various activities and regular data collection will provide near real-time and comprehensive information to the authorities leading to eliminate instances of different generic drugs being marketed with the same brand name. "Patients will be safer. The data will be used for various functions, including taking stock of manufacturers producing Active Pharmaceutical Ingredients (API).
2) New software will take care of the transition and reform the way drugs and the pharmaceutical sector is monitored and managed. Regulators will become more vigilant to act on problems of drug shortages and quality issues.
3) The new database would maintain names, addresses and licences of all manufacturers, therapeutic categories of their medicines and details like their dosages and forms
4) The rules governing the Drugs and Cosmetics Act and other laws will be amended and regular online inputs and updates regarding companies, their facilities and status of products will be made mandatory for manufacturers.
5) The database will be used to restrict manufacture or sale of specific medicines.